The pharmaceutical industry continues to be a hotbed of innovation, with activity driven by the evolution of new treatment paradigms, and the gravity of unmet needs, as well as the growing importance of technologies such as pharmacogenomics, digital therapeutics, and artificial intelligence. In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Innovation in Pharmaceuticals: Drugs for neuro-degenerative disorders.
However, not all innovations are equal and nor do they follow a constant upward trend. Instead, their evolution takes the form of an S-shaped curve that reflects their typical lifecycle from early emergence to accelerating adoption, before finally stabilising and reaching maturity.
Identifying where a particular innovation is on this journey, especially those that are in the emerging and accelerating stages, is essential for understanding their current level of adoption and the likely future trajectory and impact they will have.
110 innovations will shape the pharmaceutical industry
According to GlobalData’s Technology Foresights, which plots the S-curve for the pharmaceutical industry using innovation intensity models built on over 756,000 patents, there are 110 innovation areas that will shape the future of the industry.
Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely. Adeno-associated virus vectors, alcohol dehydrogenase compositions, and antibody serum stabilisers are some of the accelerating innovation areas, where adoption has been steadily increasing. Among maturing innovation areas are anti-influenza antibody compositions and anti-interleukin-1, which are now well established in the industry.
Innovation S-curve for the pharmaceutical industry
Drugs for neuro-degenerative disorders is a key innovation area in pharmaceutical drug development
Neurodegenerative disorders are a type of disease in which cells of the peripheral nervous system lose function over time and ultimately die. They usually get worse over time and have no cure. They may be either genetic in origin or caused by a tumour or stroke. Examples of neurodegenerative disorders include Alzheimer's disease and Parkinson's disease. Levodopa, carbidopa, COMT (catechol-o-methyl transferase) inhibitors, dopamine receptor agonists, and anticholinergics are some of the drugs used in the treatment of neurodegenerative disorders.
GlobalData’s analysis also uncovers the companies at the forefront of each innovation area and assesses the potential reach and impact of their patenting activity across different applications and geographies. According to GlobalData, there are 110+ companies, spanning technology vendors, established pharmaceutical companies, and up-and-coming start-ups engaged in the development and application of drugs for neuro-degenerative disorders.
Key players in drugs for neuro-degenerative disorders – a disruptive innovation in the pharmaceutical industry
‘Application diversity’ measures the number of different applications identified for each relevant patent and broadly splits companies into either ‘niche’ or ‘diversified’ innovators.
‘Geographic reach’ refers to the number of different countries each relevant patent is registered in and reflects the breadth of geographic application intended, ranging from ‘global’ to ‘local’.
Patent volumes related to drugs for neuro-degenerative disorders
|Company||Total patents (2010 - 2021)||Premium intelligence on the world's largest companies|
|F. Hoffmann-La Roche||270||Unlock company profile|
|AC Immune||265||Unlock company profile|
|Biogen||209||Unlock company profile|
|Lundbeck Foundation||156||Unlock company profile|
|Eli Lilly and||144||Unlock company profile|
|AbbVie||130||Unlock company profile|
|BioArctic||125||Unlock company profile|
|Prothena||114||Unlock company profile|
|Pfizer||113||Unlock company profile|
|Axon Neuroscience||112||Unlock company profile|
|Johnson & Johnson||79||Unlock company profile|
|Vivoryon Therapeutics||74||Unlock company profile|
|Abbott Laboratories||69||Unlock company profile|
|OPKO Health||55||Unlock company profile|
|OncoTherapy Science||54||Unlock company profile|
|Eisai||53||Unlock company profile|
|C2N Diagnostics||51||Unlock company profile|
|Forschungszentrum Julich||50||Unlock company profile|
|Zinfandel Pharmaceuticals||47||Unlock company profile|
|Neurimmune Holding||46||Unlock company profile|
|UCB||46||Unlock company profile|
|PTC Therapeutics||41||Unlock company profile|
|Centre National de la Recherche Scientifique||41||Unlock company profile|
|Perrigo||41||Unlock company profile|
|Clino||38||Unlock company profile|
|Proteome Sciences||35||Unlock company profile|
|Phoenix Biotechnology||34||Unlock company profile|
|Cedars-Sinai Health System||31||Unlock company profile|
|Merck & Co||31||Unlock company profile|
|Nestle||28||Unlock company profile|
|Tao Health Life Pharma||26||Unlock company profile|
|St. Jude Children’s Research Hospital||25||Unlock company profile|
|TauRx Pharmaceuticals||25||Unlock company profile|
|Grifols||24||Unlock company profile|
|Commissariat a l'Energie et aux Energies Alternatives||23||Unlock company profile|
|Takeda Pharmaceutical||22||Unlock company profile|
|Immungenetics||21||Unlock company profile|
|Curonz Holdings Company||18||Unlock company profile|
|Nippon Zoki Pharmaceutical||17||Unlock company profile|
|Galapagos||17||Unlock company profile|
|Kroger||17||Unlock company profile|
|Massachusetts General Hospital||16||Unlock company profile|
|Alzinova||16||Unlock company profile|
|ModGene Pharma||16||Unlock company profile|
|Priavoid||15||Unlock company profile|
|Yumanity Therapeutics||14||Unlock company profile|
|Neuro Bio||14||Unlock company profile|
|Vaccinex||14||Unlock company profile|
|HU Group Holdings||14||Unlock company profile|
|Sanofi||13||Unlock company profile|
Source: GlobalData Patent Analytics
F. Hoffmann-La Roche (Roche) is one of the leading patent filers in drugs for neurodegenerative disorders. The company develops drugs and diagnostics to treat major diseases. It provides medicines for the treatment of cancer, auto-immune diseases, central nervous system disorders, ophthalmological disorders, infectious diseases, and respiratory diseases. Tolcapone, Madopar, and Madopar HBS are the approved drugs for neurodegenerative diseases by Roche.
In terms of application diversity, PTC Therapeutics is the top company, followed by Aprinoia Therapeutics, and Neurimmune Holding. By means of geographic reach, Zinfandel Pharmaceuticals holds the top position. Whilst Eisai and Sanofi are in second and third positions, respectively.
To further understand the key themes and technologies disrupting the pharmaceutical industry, access GlobalData’s latest thematic research report on Pharmaceutical.